2026-04-17T07:35:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/450632025-12-19T22:58:43Zcom_2072_6col_2072_452952

urn:hdl:10230/45063 Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans Boronat Rigol, Anna, 1990- Mateus Rodriguez, Julian Andrés Soldevila-Domenech, Natalia Guerra Albà, Mercè Rodríguez-Morató, Jose, 1987- Varon, Carlota Muñoz, Daniel Barbosa, Francina Morales, Juan Carlos Gaedigk, Andreas Langohr, Klaus Covas Planells, Maria Isabel Pérez Mañá, Clara Fitó Colomer, Montserrat Tyndale, Rachel F. Torre Fornell, Rafael de la CYP2A6 CYP2D6 Cardiovascular risk Endogenous conversion Hydroxytyrosol Tyrosol Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article "Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial" 2020-07-03T06:46:40Z 2020-07-03T06:46:40Z 2019 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Data Brief. 2019; 27:104787 © 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Elsevier